SINOVAC Announces New Board Member
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the ' Board ') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board.
Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School.
Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac ®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive ®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive ®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1 ®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu ®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company's website at www.sinovac.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
IAS Expands Tools To Help Meta Ads Perform Better On Facebook And Instagram
Integral Ad Science (NASDAQ:IAS) on Wednesday announced the launch of new contextual category reporting for Meta Platforms (NASDAQ:META), expanding measurement reporting across Facebook and Instagram Feed and Reels. The company said in a press release that this launch demonstrates IAS and Meta's continued collaboration to deliver independent third-party measurement and optimization tools to support advertisers' brand suitability and performance goals. Meta Platforms could potentially generate over $10 billion in annual ad revenue from its WhatsApp messaging service by 2028, according to Evercore ISI analyst Mark Mahaney, assuming average advertising revenue of $6 per daily user and boost daily usage of the Updates tab to 1.7 billion users by reported earnings of $6.43 per share, topping analyst estimates of $5.21 per share, and total revenue increased 16%. Advertising drove revenue, with ad impressions jumping 5% and the average price per ad increasing by 10%. Wall Street analysts, including JP Morgan, highlighted Meta's new AI models, Andromeda and GEM, which deliver tangible improvements in advertising. Andromeda, powered by advanced hardware, has increased ad quality by 8%, while GEM has boosted ad conversions on Reels by up to 5%, as per JPMorgan analyst Doug Anmuth. The analysts continue to view Meta as the best-positioned digital ad player. Price Action: META stock was trading higher by 0.58% to $701.29 premarket at last check Wednesday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? INTEGRAL AD SCIENCE HOLDI (IAS): Free Stock Analysis Report This article IAS Expands Tools To Help Meta Ads Perform Better On Facebook And Instagram originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Miami Herald
26 minutes ago
- Miami Herald
Popular restaurant chain franchisee files Chapter 11 bankruptcy
The Covid pandemic forced many restaurants to adjust to a new normal based on health safety protocols meant to prevent the spread of the potentially deadly disease. In March 2020, restaurants across the nation closed their doors but soon reopened with social distancing and safety protocols. Don't miss the move: Subscribe to TheStreet's free daily newsletter Fast-food restaurants were designed with take-out and drive-thru systems that allowed them to continue operating as if nothing happened, though many shut their dining rooms for many months for safety reasons. Related: Major nationwide trucking company files for Chapter 11 bankruptcy Casual restaurants did their best to offer take-out and curbside pick-up systems, but some restaurant concepts, such as buffets, were not designed for such systems, did not adopt them, and many went out of business. Some of the most significant restaurants to suffer the effects of the pandemic filed for bankruptcy over the last year. Seafood chain Red Lobster, which filed for bankruptcy in May 2024, closed about 187 restaurants. The dining chain emerged from Chapter 11 in September 2024 and now operates about 478 locations in 44 states. More bankruptcy: Iconic auto repair chain franchise files Chapter 11 bankruptcyPopular beer brand closes down and files Chapter 7 bankruptcyPopular vodka and gin brand files for Chapter 11 bankruptcy Bar and grill chain TGI Fridays had 161 U.S. locations when it filed for Chapter 11 bankruptcy on Nov. 2, 2024, to reorganize and closed 76 locations. The restaurant chain listed 85 U.S. locations on its website in April. Italian restaurant chain Buca di Beppo closed 18 locations last year before it filed for Chapter 11 bankruptcy protection on Aug. 4, 2024, to reorganize its business with the support of its lenders. The restaurant chain on Nov. 4 won approval to sell its 44 remaining corporate-owned restaurants to its lender Main Street Capital Corp., with a credit bid of $27 million. But it was buffet restaurants that were hit the hardest by the pandemic, with several filing for bankruptcy months after the beginning of the pandemic. National buffet chain Hometown Buffet's parent Fresh Acquisitions LLC filed for Chapter 11 in April 2021, suffering from the effects of the Covid pandemic and closed down permanently. The chain had struggled for years as the previous owner, Buffets Inc., filed for bankruptcy in 2008 and 2012 before selling the company in 2015, just before the chain's new owners filed Chapter 11 again in 2016. Other buffet restaurants also felt the harsh effects of the Covid pandemic and were forced to file for bankruptcy. Golden Corral franchisees were among the buffet restaurant owners to file for bankruptcy as the pandemic subsided. The buffet restaurant chain's largest franchisee at the time, 1069 Restaurant Group LLC, filed for Chapter 11 bankruptcy in October 2020, and its second-largest franchisee, Platinum Corral LLC, filed for bankruptcy in April now fast-forward to 2025, and another franchisee of Golden Corral has filed for Chapter 11 bankruptcy to reorganize its business. South Texas Corral LLC filed its Subchapter V petition on June 17 in the U.S. Bankruptcy Court for the Southern District of Texas, listing $150,000 in assets and $1.64 million in liabilities. Related: Popular smoothie chain franchisee files for Chapter 11 bankruptcy The Brownsville, Texas, Golden Corral franchisee did not reveal a reason for filing for bankruptcy in its petition. Golden Corral, which launched in Fayetteville, N.C., in 1973, operates about 351 restaurants in 39 states and Puerto Rico, with most of them run by franchisees. The restaurant chain claims to be the nation's largest grill buffet restaurant chain. It serves all-you-can-eat breakfast, lunch, and dinner, featuring various grilled steaks, ribs, barbecue beef, brisket pot roast, meatloaf, burgers, sandwiches, chicken and wings, soups and salads, and various breakfast items. Related: Popular local Dairy Queen rival files for Chapter 11 bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
USA Today
35 minutes ago
- USA Today
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the 'Company'), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics. Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA ( Nimbus has been rising globally since Spring according to WHO ( Nimbus causes 'razor-sharp' sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms. Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC. Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus. Recently, the Influenza A H5N1 virus from a dairy worker in Michigan was found to be capable of airborne transmission in a ferret animal model [1] ( This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans. Additionally, a new genotype of H5N1 in Cambodia has caused four fatalities and fifth severe infection as of today ( NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes. NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2. Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections. NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events. COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes. NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes. NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children. NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient. 'NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,' said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, 'We have US-based cGMP manufacturing capabilities already set up as well.' Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines. Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time). Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA. The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread. About NanoViricides NanoViricides, Inc. (the 'Company') ( is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. info@ Public Relations Contact: ir@ [1] Brock N, Pulit-Penaloza JA, Belser JA, et al. Avian Influenza A(H5N1) Isolated from Dairy Farm Worker, Michigan, USA. Emerging Infectious Diseases. 2025;31(6):1253-1256. doi:10.3201/eid3106.250386. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire
